Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in
HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.